Quick Answer
HOOKIPA Pharma Inc. reported Cash and Equivalents of $39.68 million for fiscal year 2024.
HOOKIPA Pharma Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $39.68M | -66.1% |
| 2023 | $117.10M | +4.1% |
| 2022 | $112.49M | +70.6% |
| 2021 | $65.92M | -53.8% |
| 2020 | $142.74M | +26.2% |
| 2019 | $113.15M | +132.9% |
| 2018 | $48.58M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| March 31, 2025 | $40.28M | -56.6% | +1.5% |
| December 31, 2024 | $39.68M | -66.1% | -33.6% |
| September 30, 2024 | $59.75M | -44.5% | -22.6% |
| June 30, 2024 | $77.15M | -43.1% | -16.8% |
| March 31, 2024 | $92.75M | -15.4% | -20.8% |
| December 31, 2023 | $117.10M | +4.1% | +8.7% |
| September 30, 2023 | $107.68M | +7.9% | -20.6% |
| June 30, 2023 | $135.59M | +15.0% | +23.7% |
- HOOKIPA Pharma Inc. showed a decrease of -66.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2024 period, HOOKIPA Pharma Inc.’s cash and equivalents has declined by 18.3% (from $48.58 million to $39.68 million).
- The most recent figure is from HOOKIPA Pharma Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on February 28, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: